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Abstract
Background: Efforts to improve research outcomes have resulted in genomic researchers being confronted with
complex and seemingly contradictory instructions about how to perform their tasks. Over the past decade, there
has been increasing pressure on university researchers to commercialize their work. Concurrently, they are
encouraged to collaborate, share data and disseminate new knowledge quickly (that is, to adopt an open science
model) in order to foster scientific progress, meet humanitarian goals, and to maximize the impact of their
research.
Discussion: We present selected guidelines from three countries (Canada, United States, and United Kingdom)
situated at the forefront of genomics to illustrate this potential policy conflict. Examining the innovation ecosystem
and the messages conveyed by the different policies surveyed, we further investigate the inconsistencies between
open science and commercialization policies.
Summary: Commercialization and open science are not necessarily irreconcilable and could instead be envisioned
as complementary elements of a more holistic innovation framework. Given the exploratory nature of our study,
we wish to point out the need to gather additional evidence on the coexistence of open science and
commercialization policies and on its impact, both positive and negative, on genomics academic research.
Background
Article 27 of the Universal Declaration of Human Rights
(1949), Article 15 of the International Covenant on Eco-
nomic, Social and Cultural Rights (1966), and Article 15
of the UNESCO Universal Declaration on Bioethics and
Human Rights (2005) all articulate the obligation to
share scientific knowledge and the right to share in the
benefits of scientific knowledge. But like the concept of
‘benefit sharing’, the idea of optimally sharing and maxi-
mally utilising scientific knowledge is fraught with com-
plexity, confusion, and policies at seemingly stark cross-
purposes. The matter is further complicated by the fact
that research is becoming more expensive, research
structures are growing more complex and fractured, and
innovation levels, at least in the pharmaceutical setting,
are not increasing [1].
Efforts to meet these legally mandated needs and to
simultaneously improve research outcomes have resulted
in researchers being confronted with complex and see-
mingly contradictory instructions about how to perform
their tasks. This is particularly vexing for university-
based genomics researchers. On the one hand, they are
told to commercialize their research by patenting, licen-
sing, and forming close partnerships with industry,
which has particular skills, financial assets to facilitate
the translation of knowledge into products, and objec-
tives. It is presumed that this will generate maximum
wealth and benefit through the quicker introduction of
socially useful knowledge and products. On the other
hand, researchers are encouraged to share data and dis-
seminate knowledge quickly (that is, to adopt an open
science model) so as to foster scientific progress, meet
humanitarian goals, and (again) maximize the impact of
research.
As genomics research leaders with mature regulatory
frameworks and enviable regulatory capacity, and as reg-
ular expositors of human rights rhetoric, Canada, the
United Kingdom (UK), and the United States (US)
might be expected to take a lead in clarifying the mes-
sage to researchers and rationalizing the expectations to
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regard (for example, Japan and the BRIC countries -
which they are held. While we recognize that other jur-
isdictions will have an equally strong interest in this
Brazil, Russia, India and China), space limits our ability
to address them, and, in any event, this paper is not
intended as a comprehensive survey/study. Below we
discuss the prevalence of these conflicting messages in
Canada, the UK, the US, and internationally, and high-
light some of the practical difficulties they are creating
within the global research community. In doing so, we
focus on the bioscience sector, which has been the sub-
ject of significant expectation and support, and we offer




While there are numerous social and political forces at
work in generating the above-noted pressure to com-
mercialize research, two in particular are noteworthy.
The first relates to the need, recognized by governments
and imposed on researchers, to secure research funds
from sources other than government [2-5]. The second,
and arguably more important, force is the desire to posi-
tion university research as an engine of economic
growth. The pressure to ‘translate’ has grown sharper
since the addition of a ‘third role’ for universities in the
1990s; to ‘knowledge producer’ and ‘knowledge trans-
mitter’ was added ‘economic developer’ [6].
This paradigm shift has resulted in increasing expec-
tations that university researchers will build ties with
industry and produce research with commercial poten-
tial. In the biotechnology sector, for example, knowl-
edge-driven biotech start-up clusters associated with
universities were prompted [7]. By 2003, the high tech-
nology cluster in Oxfordshire, England contained some
1,400 firms and employed some 37,000 people [8]. Pur-
suing this partnering agenda has demanded that uni-
versities overcome existing cultural values - many of
which contributed to the excellence for which they
became known in the first place - and that they adopt
a more entrepreneurial approach to their activities [9].
While the commercialization of academic research has
generated mixed results at best [10,11], the imperative
to commercialize university research persists, and can
be found throughout the world in both soft ‘nudges’
(expressed in policy statements, university technology
transfer office (TTO) mandates and practices, funding
opportunities, and intellectual property (IP) ‘toolkits’
available to researchers), and hard obligations
(expressed in research networks and public funding
agency requirements and agreements). Importantly, as
highlighted in Table 1 this pressure is more than mere
political posturing or bureaucratic musing. The idea
that researchers should commercialize their work is
part of the official mandate of public funding agencies
and research networks, as demonstrated in the review
below.
In Canada, the National Research Council has adopted
a strategy that ‘downplays basic research’ and empha-
sizes work that will ‘attract industry partners and gener-
ate revenue’ [12], a shift that has been reproduced at the
provincial level (for example, see the Alberta experience
[13]). The commercialization objective has even been
explicitly built into the enabling legislation of the Cana-
dian Institutes of Health Research (CIHR). One of the
legislated objectives of CIHR is ‘facilitating the commer-
cialization of health research in Canada and promoting
economic development through health research in
Canada’ [14]. The Canadian Networks of Centres of
Excellence Program, developed in 1989 to mobilize
Canada’s best research teams, has been developed
around the idea of altering the academic culture and
managing scientific research to make it more commer-
cial [15]. In its recent 20th anniversary report, the Cana-
dian Networks of Centres of Excellence stated that it
would focus in the coming years on increasing industrial
investment in research and development partnership
and accelerating the commercialization of technologies,
products and services [16].
This emphasis is recreated at the science-specific level.
For example, the Canadian Stem Cell Network is man-
dated to support the commercialization of its funded
research; since 2005, it has aligned its research program
to conform to the three main routes to market (cells,
drugs, and tools), and has erected funds and produced
practical advice to facilitate commercialization [17]. In
2010, Genome Canada, an agency that supports large-
scale genomic and proteomic projects, launched a pilot
program called Entrepreneurship Education in Geno-
mics to facilitate education of the Canadian genomics
research community on how to create and capture value
from their research and translate their discoveries into
marketable applications, products, technologies, systems
and processes [18]. This can be seen as an application
of its Guidelines for Funding Large-scale Genomics
Research Projects [19], which include effectiveness eva-
luations of commercialization plans for funding geno-
mics projects.
As in Canada, numerous UK government policies and
funding programs have been aimed at encouraging and
improving university-to-business technology transfer,
including the University Challenge and HEROBC
[20,21]. In October 2011, the UK government
announced a £220 million program to translate Britain’s
research strengths, including those around stem cell
research, into manufacturing success by facilitating aca-
demia-industry partnering through joint centers of
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excellence [22]. This notion of university-industry colla-
boration and commercialization of outputs has spilled
over into funding agency policies. For example, the
Medical Research Council (MRC) Good Research Prac-
tice policy articulates an economic mission and stipu-
lates that MRC-funded researchers are expected to
maximize the prospects of research being taken into
practice through the commercial route by protecting IP
rights [23]. This policy also states that traditionally com-
mercial and knowledge-enclosing material transfer
agreements and confidentiality agreements are impor-
tant for protecting resources that may have value. Simi-
larly, the MRC’s Operational and Ethical Guidelines for
Human Tissue and Biological Samples for Use in
Research [24] state that the MRC’s mission is to support
research that will ultimately benefit human health and
that commercial involvement is crucial to this effort.
Thus, access by the commercial sector to samples of
human material collected in the course of MRC-funded
research should be facilitated. Finally, under its Transla-
tional Research Strategy [25], the MRC acknowledges
‘the important role collaborations can play in helping to
meet our priorities of translating research into health-
care improvements and enhancing economic prosperity’,
and it ‘welcomes applications involving academic/indus-
try collaborations.’
In its Strategic Plan [26], the UK’s Biotechnology and
Biomedical Sciences Research Council (BBSRC) articu-
lates three ‘enabling themes’: (1) knowledge exchange,
innovation and skills; (2) exploiting new ways of
Table 1 Policies and guidelines encouraging commercialization
Canadian Institutes of Health Research (CIHR), Canadian Institutes of
Health Research Act (2000)
The objective of the CIHR is to excel, according to internationally accepted
standards of scientific excellence, in the creation of new knowledge and its
translation into improved health for Canadians, more effective health
services and products and a strengthened Canadian health care system, by
... encouraging innovation, facilitating the commercialization of health
research in Canada and promoting economic development through health
research in Canada
Genome Canada, Guidelines for Funding Large-scale Genomics Research
Projects (2010)
Appendix A - Evaluation Criteria ...
B. Benefits for Canada
2. The demonstration of how anticipated results will contribute to job
creation, economic growth, development of a product, service, licenses or
the creation of start-ups
3. The effectiveness of the proposed plans for commercialization,
technology transfer and the handling of intellectual property (where
applicable)...
4. The potential for use or commercialization (where appropriate) of the
anticipated results and the extent to which the proposed research will
further the development of new methods, perspectives and/or technology
Stem Cell Network (Canada), Commercialization strategy (2011) The Network’s commercialization strategy is driven by its mandate to
support the commercialization of its funded research, and by a desire to act
more broadly as a catalyst for commercialization across the whole Canadian
stem cell research sector
California Institute for Regenerative Medicine (CIRM; US), CIRM Stem
Cell Grant Regulations (2009)
...a Grantee shall make reasonable efforts to develop, commercialize or
otherwise bring to practical application CIRM-funded technology or CIRM-
funded inventions
Howard Hughes Medical Institute (HHMI; US), Intellectual Property and
Licensing Policies - Licensing by Host Institutions to Companies (2008)
...the host institution is responsible for efforts to commercialize intellectual
property developed in HHMI laboratories at the site
Howard Hughes Medical Institute (US), Intellectual Property Policy
(2007)
The host institution’s technology transfer office takes the lead on licensing
or other commercialization activities with respect to subject property
developed at the site
Department of Health (UK), Research Governance Framework for Health
and Social Care, 2d edition (2005)
Consideration must be given to the exploitation of intellectual property
rights
Medical Research Council (UK), Good Research Practice (2005) MRC-funded researchers are expected to maximize the prospects of
research being taken into practice through the commercial route by
protecting intellectual property rights
Medical Research Council (MRC; UK), Translational Research Strategy
(2008)
The MRC recognizes the important role collaborations can play in helping to
meet our priorities of translating research into healthcare improvements and
enhancing economic prosperity. As such, the MRC welcomes applications
involving academic/industry collaborations...
Biotechnology and Biomedical Sciences Research Council (BBSRC; UK),
Strategic Plan (2010)
BBSRC seeks to understand the most critical bioscience challenges facing
industry and create opportunities for engagement between academia and
industry. This ensures that the research and training we fund promote
innovation and generate impact. We will increase the range and depth of
our interactions with business ...
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working; and (3) partnerships. Regarding the first theme,
the BBSRC explains:
BBSRC, in partnership with other funders, will
develop a better understanding of the various routes
and barriers to translation in different sectors. We
will seek to deliver innovative solutions, focusing not
only on intellectual property but more broadly on
intellectual assets. We will also increase support for
people in translational roles, and develop enterprise
skills in researchers. ... BBSRC sustains a high quality
research base that supports innovation in important
UK business sectors including agriculture, food and
drink, pharmaceuticals, healthcare, chemicals and
biotechnology. Discovery and production activities in
these industries depend on scientific advances in the
academic community. BBSRC seeks to understand
the most critical bioscience challenges facing indus-
try and create opportunities for engagement between
academia and industry. This ensures that the
research and training we fund promote innovation
and generate impact. We will increase the range and
depth of our interactions with business...
These commercialization policies are not limited to
universities and their primary funders, but are also
advanced by other traditionally solidarity-based institu-
tions. For example, the UK Department of Health, in its
Research Governance Framework for Health and Social
Care [27], states: ‘Consideration must be given to the
exploitation of intellectual property rights.’ It has also
identified the NHS as an important contributor to inno-
vation capable of capturing new technologies and ensur-
ing that those inventions that can make more income
available for improving the health service are appropri-
ately developed and exploited.
In the US, which has a long history of commercializ-
ing university research [28,29], the heightened pressure
to work with industry is perhaps best exemplified by
President Obama’s 2011 State of the Union address
where he unveiled his ‘Startup America’ initiative [30]
and called upon the research community to help stimu-
late the economy [31]. He characterized this wealth-
and job-creation plea as ‘our generation’s Sputnik
moment’ [31,32]. President Obama’s initiative is multi-
faceted but seeks to boost overall innovation and entre-
preneurship in America by encouraging private invest-
ment in startups. One part of this initiative is the
National Science Foundation’s Innovation Corps (I-
Corps) program, which, through public-private partner-
ships and funding opportunities, will ‘guide promising
research with commercial potential out of university
laboratories’ of current or previously funded National
Science Foundation grantees [33]. Although adopting a
more nuanced perspective on commercialization, a
recent report from the National Research Council Com-
mittee on management of university IP nevertheless
concluded that ‘the goal of expeditious and wide disse-
mination of discoveries and inventions places intellec-
tual property based technology transfer squarely within
the research university’s core missions of discovery,
learning, and the promotion of social well-being’ [34].
Finally, as in Canada, the commercialization imperative
is reproduced at the state level (for example, see the
California Institute for Regenerative Medicine [35]), and
at the private philanthropic level (for example, see the
Howard Hughes Medical Institute [36]).
Importantly, empirical research has confirmed the
mounting intensity of this commercialization pressure.
For example, a recent study of the perceptions of Cana-
dian TTOs found that, ‘[w]ithout exception, all technol-
ogy transfer professionals interviewed believed that
commercialization pressure has increased over the past
10-15 years’ [37]. As noted by one TTO respondent
when asked if commercialization expectations have
intensified: ‘Very much so, dramatic. The pressure is
coming from the government, the federal government
and provincial government.’ So not only are pressures
mounting, but researchers are becoming increasingly
sensitive to those pressures. Studies of the Australian
[38] and Canadian genomics and stem cell research
communities (both of researchers and the public) have
also illustrated some of the challenges and frustrations
created by the increasing commercialization of academic
research [39-41], including the disconnection with the
fundamental research reality, negative impact of com-
mercial secrecy on academic research, and ambivalence
of researchers toward gene patents.
Open scientific collaboration
Despite the above policies, and perhaps following the
mixed results achieved under them, there is also a
movement, under a seemingly opposing ethos, to openly
share scientific knowledge and to forge a model of ‘open
scientific collaboration’. Though removed in many ways
from the open access and open innovation models that
transformed the information and communication and
the business sectors [42,43], it reflects them in its ambi-
tion to create a more open, collegial, and collaborative
research environment, and it has been advanced over
the past decade by several moves in a wide array of dis-
ciplines [44,45]. A common broad justification for open
scientific collaboration (and increased sharing) is the
idea, expressed succinctly by the BBSRC, that making
data more readily available will reinforce open scientific
enquiry and stimulate new investigations and analyses,
and efforts at doing so should be led by the scientific
community to ensure (1) data quality, (2) the formation
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of good practice, and (3) the natural embedding of shar-
ing into the scientific culture [26].
In the bioscience sectors, this model has been pushed
by leading international organizations and the research
community itself [46-48]. UNESCO’s Universal Declara-
tion on the Human Genome & Human Rights [49],
which is aimed at member states and research stake-
holders, emphasizes the right of scientific inquiry within
a human rights framework and subject to dignity-based
limitations (Articles 10 to 15). It states that benefits
should be shared (Article 12), articulates the duty to
present and utilize findings (Article 13), and directs
states and organizations to cooperate and exchange
scientific knowledge and information (Article 19).
UNESCO’s International Declaration on Human Genetic
Data [50] aims to foster international medical, scientific
and cultural cooperation and fair access, and interna-
tional dissemination of scientific knowledge, particularly
between industrialized and developing countries (Article
18). It directs researchers to establish cooperative rela-
tionships based on mutual respect, and to circulate data
so as to foster knowledge-sharing. The International
Organisation of the Human Genome (HUGO), which
considers databases and genetic data to be global public
goods, has also been a proponent of open data sharing
in its various ethics policies [51].
Similarly, the Organisation for Economic Co-operation
and Development (OECD), in its Principles and Guide-
lines for Access to Research Data from Public Funding
[52], states that the value of data lies in their use. Most
importantly, it states that full and open access to scienti-
fic data should be adopted as the international norm
associated with publicly funded research, so that expen-
sive and unnecessary duplication of data collection can
be avoided and the overall efficiency of publicly funded
research can be improved. While these guidelines note
the importance of protecting the rights and interests of
all stakeholders, and concede that access to data might
be limited on certain grounds (including national secur-
ity, trade secrets, conservation, legal process, and privacy
and confidentiality), they approach these limitations with
a view towards preserving as much sharing potential as
possible.
Strangely, given the commercialization positions
already identified above, some of the strongest open
science statements have been proclaimed by the
research funding agencies themselves. For example,
Genome Canada has committed itself to the principle of
rapid sharing of its financed research projects and
unique resources. Its Data Release and Resource Sharing
Policy [53] and its Policy on Access to Research Publica-
tions [54] convey the key elements of this position to
grant beneficiaries. Moreover, Genome Canada will
review the beneficiaries’ proposed data and resource
sharing plan to verify that it conforms to Genome
Canada policies and that funds will not flow until an
acceptable plan has been approved and incorporated
into the terms of award. Somewhat in paradox with its
commercialization mandate, CIHR expresses in its Policy
on Access to Research Outputs [55] its ‘fundamental
interest in ensuring that the findings that result from
the research it funds, including research publications
and publication-related data, are available to the widest
possible audience, and at the earliest possible
opportunity.’
In the UK, the MRC Data Sharing Policy [56] charac-
terizes publicly funded research data as a public good
and stipulates that restrictions imposed on access to
publicly funded data should be limited. Data should be
made available to the maximum extent possible, and
should be shared in a timely and responsible manner.
As such, the MRC has made data-sharing a prerequisite
to funding, and has directed that data-sharers receive
full and appropriate recognition. The BBSRC Data Shar-
ing Policy [57] opines that bioscience datasets are
important to the wider scientific community, and that
re-use of data can lead to new scientific understanding.
Thus, it offers substantive support for managing and
sharing data and it instructs other funders, academic
institutions, and new users to recognize sharing efforts.
The BBSRC policy elaborates on data-sharing methods
and instructs researchers to retain the data in accessible
formats for a period of 10 years after project comple-
tion, in keeping with BBSRC guidance on good scientific
practice. Likewise, the Wellcome Trust Policy on Data
Management and Sharing [58] stipulates that it expects
researchers to maximize the availability of data with as
few restrictions as possible, and it articulates the belief
that success in maximizing the value of research
depends on fostering a culture in which both data gen-
erators and data users act with integrity and transpar-
ency in managing, using, and sharing data. To foster
this, it states that all data users must acknowledge the
sources of their data, and must work cooperatively to:
(1) ensure that datasets are developed and maintained
for use by the research community; (2) recognize the
contributions of researchers who generate, preserve, and
share datasets; and (3) develop best practice for data
sharing in different fields, recognizing that different data
types raise distinct issues and challenges.
The Wellcome Trust requires applicants to submit a
data management and sharing plan whenever research is
likely to generate data that will hold significant value as
a resource for the wider research community.
In the US, the National Institutes of Health (NIH), in
its Final Statement on Sharing Research Data [59],
explains the Institutes’ position to the effect that ‘data
sharing is essential for expedited translation of research
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results into knowledge, products, and procedures to
improve human health.’ More interesting, the statement
requires that applicants seeking $500,000 or more in
direct costs in any year of the project period must
include a data-sharing plan in their application, stating
how they will share the data or, if they cannot share the
data, why not. The Global Health Data Access Principles
of the Bill & Melinda Gates Foundation has adopted a
similar approach, stipulating that, when possible, data
should be deposited in public-access repositories. If this
is not possible, prospective grantees should propose
alternatives for access, with consideration given to the
ease of discovery of the existence of the data set and
maintenance of long-term access [60]. The Howard
Hughes Medical Institute, while expecting an investiga-
tor’s host institution to commercialize research outputs,
also has a Sharing of Publication-related Materials,
Data and Software policy [61], which states its mission
supports broad dissemination of research tools, and
requires databases that are too large to be included in a
publication (but which are nonetheless integral to the
publication) be made freely available by other means
(for example, on-line at no cost, with no restriction on
research use, and in a highly accessible manner [61]).
This open scientific collaboration philosophy has
resulted in the creation of a range of open access jour-
nals, publicly accessible biobanks, and more. Recently, it
has led a large group of major health research funders
to issue a Joint Statement of Purpose [62], which sets
out their belief that making datasets available to those
beyond the original collectors in a timely and responsi-
ble manner will generate (1) faster progress in improv-
ing health, (2) better value for money, and (3) higher
quality science. The signatories have agreed to work
jointly and to call on other actors, including govern-
ments, to adopt data-access policies that promote shar-
ing and use. The statement is founded on the principles
of equity, ethics, and efficiency, and goes on to outline
immediate goals and longer-term aspirations, which is
important in a climate where academic researchers have
been encouraged to seek commercial opportunities and
IP rights over their inventions [63]. A sampling of open
science research policies is offered in Table 2.
A policy conflict?
On the surface, these policy trends seem to create an
untenable situation within the research community. We
might reasonably ask if there is, in fact, an irreconcilable
conflict? Can researchers reasonably be expected to
embrace the commercialization and the ‘open science’
imperatives? And what is the impact of one upon the
other?
Before briefly considering these questions, we should
say a word about the two models. First, many are
skeptical that the narrow commercialization agenda will
work. As noted by Hopkins, et al. [64], ‘[t]he translation
of advances in bioscience into new technology is far
more difficult, costly and time-consuming than many
policymakers believe.’ There is evidence that approaches
to commercialization, such as partnering with industry
and the promotion of start-up companies, simply do not
work [65]. Moreover, the early perception that patents,
a common outcome of commercialization, could pro-
cure a substantial source of income for academic institu-
tions has now been strongly refuted by the available
evidence [34]. Biotechnology patents have also raised
substantial ethical and scientific controversies and are
facing increasing legal challenges (Oliver Brustle v.
Greenpeace e. V. (2011), Association for Molecular
Pathology et al. v. USPTO et al. (2010; overturned in
part by the Court of Appeals for the Federal Circuit)).
To be fair, open scientific collaborations in biotechnol-
ogy are still in their infancy, and, like commercialization,
have much to prove in terms of delivering economic,
social, or clinical benefits [66], though there certainly
have been anecdotal examples of open models succeed-
ing [45,67]. One of the major challenges for proponents
of such collaborative models will be to convince govern-
ments and industry of the value of this particular busi-
ness model, and to obtain their participation in more
open initiatives.
On the question of irreconcilability, more than a few
scholars have suggested that the pressure on researchers
to obtain IP rights, a by-product of the commercializa-
tion instruction, conflicts directly with the idea of free
exchange of scientific knowledge [68]. While the data
on the impact of patents is equivocal (there is, for exam-
ple, little solid research that shows a clear ‘anti-com-
mons’ effect [32,69,70], research gives teeth to the
concern that commercialization pressure hurts open
scientific collaboration [71]. One recent study concluded
that industry sponsorship of university research ‘jeopar-
dizes public disclosure of academic research’ [72]. Other
studies have found that commercialization activity nega-
tively impacts researcher collaboration [73]. This
occurred despite researchers being part of a collabora-
tive network. Given that collaboration is an important
element of an open (scientific) culture, this research,
which is buttressed by other recent work [74], supports
the contention that there is, at a minimum, a serious
policy tension. Indeed, it was concluded that, ‘policies
directed at enhancing collaborative networks and poli-
cies directed at commercialization are moderately antag-
onistic’ [73]. This is a position shared by some of the
TTO respondents in that study, who felt that (the domi-
nant) commercialization pressure cut against the tradi-
tional mandate of universities, which, as one TTO
official put it, was ‘the discovery of new knowledge’ [37].
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Table 2 Policies and guidelines promoting open science
Universal Declaration on the Human Genome and Human Rights (1997) Article 12(a):
Benefits from advances in biology, genetics and medicine, concerning the
human genome, shall be made available to all, with due regard for the
dignity and human rights of each individual
International Declaration on Human Genetic Data (2003) Article 18(c):
Researchers should endeavour to establish cooperative relationships,
based on mutual respect with regard to scientific and ethical matters and,
subject to the provisions of Article 14, should encourage the free
circulation of human genetic data and human proteomic data in order to
foster the sharing of scientific knowledge, provided that the principles set
out in this Declaration are observed by the parties concerned. To this
end, they should also endeavour to publish in due course the results of
their research
HUGO, Statement on Human Genomic Databases (2002) Human genomic databases are global public goods.
...
The free flow of data...should be encouraged
Bermuda Principles (1996) ...all human genomic sequence information, generated by centres funded
for large-scale human sequencing, should be freely available and in the
public domain in order to encourage research and development and to
maximise its benefit to society
Fort Lauderdale Agreement (2003) Rapid release of DNA sequence data should be extended to all sequence
data.
Rapid pre-publication release should apply to other types of data from
other large-scale production centers specially established as ‘community
resource projects’
Toronto Statement (2009) ...attendees endorsed the value of rapid pre-publication data release for
large reference datasets in biology and medicine that have broad utility
and agreed that pre-publication data release should go beyond genomics
and proteomics studies to other datasets - including chemical structure,
metabolomic, and RNAi datasets, and annotated clinical resources
(cohorts, tissue banks, and case-control studies)
Joint Funders Statement (2011) Goals: ...
Data sharing is recognized as a professional achievement
Funders and employers of researchers recognize data management and
sharing of well-managed datasets as an important professional indicator
of success in research
Well documented data sets are available for secondary analysis
Data collected for health research are made available to the scientific
community for analysis which adds value to existing knowledge and
which leads to improvements in health
Organisation for Economic Cooperation and Development (OECD),
Principles and Guidelines for Access to Research Data from Public Funding
(2007)
Full and open access to scientific data should be adopted as the
international norm associated with publicly funded research
Canadian Institutes of Health Research, Policy on Access to Research
Outputs (2007)
...CIHR has a fundamental interest in ensuring that the findings that result
from the research it funds, including research publications and
publication-related data, are available to the widest possible audience,
and at the earliest possible opportunity
Genome Canada, Data Release and Resource Sharing Policy (2008) Genome Canada is committed to the principle of rapid data release and
sharing of unique resources to the scientific community; Genome Canada-
funded projects must therefore share data and resources in a timely
fashion with minimal or no restrictions.
....
Genome Canada applicants must provide a Data and Resource Sharing
Plan as part of their application
Genome Canada, Policy on Access to Research Publications (2008) Research publications are an important output of the research funded by
Genome Canada and free, online access to these publications is
paramount. Genome Canada recommends that peer reviewed
publications that have been supported, in whole or in part, by Genome
Canada be made freely accessible online, in a central or institutional
repository, as soon as possible, and, at the latest, six months after the
publication date
National Institutes of Health (US), Final Statement on Sharing Research
Data (2003)
...data sharing is essential for expedited translation of research results into
knowledge, products, and procedures to improve human health.
...
...all investigator-initiated applications with direct costs greater than
$500,000 in any single year will be expected to address data sharing in
their application
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Despite the above, we take a more circumspect view
on the question of irreconcilability of commercialization,
on the one hand, and open scientific collaboration, on
the other. Certainly there is a tension! But we should
not presume that this tension is necessarily (all) bad.
Managing the coexisting policy mandates (and tension),
and keeping everyone (reasonably) happy will be a
major policy and practical challenge in the coming
years, but it is arguable that the dual pressures creates a
balance that, in the aggregate, could be good for both
science and society. Moreover, it is possible that the two
mandates do not always conflict or are not always
necessarily irreconcilable [75-77]. Ideally, both commer-
cialization and open scientific collaboration could be
viewed as complementary strategies within a larger fra-
mework of activities aimed at getting the optimal social
and economical value from university research that
must be alternatively chosen based on prevailing cir-
cumstances [11].
Openness in genomics is being promoted by the same
research funding agencies that have been mandated for
the last three decades with promoting commercializa-
tion. This at least offers the possibility of a uniform (or
joined-up) voice being found. Of course, the positive
potential of this dualism relies on funding agencies and
research institutions collaborating to avoid the uncoor-
dinated super-position of one innovation model over the
other. Again, a clear message must be forged by the dis-
tinct yet closely tied communities that are relevant to
the scientific undertaking, namely the political and the
funding community, the international non-governmental
organizations, and the research communities. Funding
and institutional policies, research guidelines, and pro-
ject protocols must all be harmonized insofar as they
must all recognize the dualism and permit those operat-
ing on the ground to choose the course (or courses)
that most effectively satisfies the needs of the public.
Currently, the appearance and language of conflict
together with the often unreflexive nature of the balan-
cing of apparently diverging interests is a real problem,
albeit one that deserves further empirical study.
Researchers have little space to come to grips with how
they might, in practice, embrace both imperatives. Bear-
ing this in mind, important questions for further empiri-
cal research include: to what extent do researchers sense
this policy tension? If they perceive it, what effect is it
having on their behavior? And how should individual
researchers go about determining how to complete a
grant application section covering the expected societal
or economic benefit of research? (Should they be ‘con-
servative’ and talk about short-term commercialization,
job creation and patenting opportunities, or should they
take a chance and discuss open and rapid dissemination,
societal benefits, and the advancement of science?)
Table 2 Policies and guidelines promoting open science (Continued)
Bill & Melinda Gates Foundation (US), Global Health Data Access Principles
(2011)
Grantees will be required...to facilitate the prompt and broad
dissemination of data.
...
When possible, data should be deposited into public-access repositories
California Institute for Regenerative Medicine (CIRM; US), Stem Cell Grant
Regulations (2006)
Grantees shall share biomedical materials first created under CIRM funding
and described in published scientific articles for research purposes in
California within 60 days of receipt of a request and without bias as to
the affiliation of the requestor unless legally precluded. ...[S]uch materials
are to be shared without cost or at the actual cost of providing the
material without an allocation of costs for overhead, research, discovery or
other non-direct costs of providing the material
Howard Hughes Medical Institute (HHMI; US), Sharing of Publication-
Related Materials, Data and Software (2007)
...the mission of HHMI is to move biomedical science forward, and broad
dissemination of research tools and reagents created by its investigators
very much supports that mission...
Medical Research Council (UK), Data Sharing Policy (2011) Research is a public good and, as such, data should be made available to
the maximum extent possible, and should be shared in a timely and
responsible manner
Biotechnology and Biomedical Sciences Research Council (UK), Data
Sharing Policy (2010)
Members of the community are expected and encouraged to practise
and promote data sharing, determine standards and best practice, and
create a scientific culture in which data sharing is embedded. BBSRC will
provide support and funding to facilitate this.
...
BBSRC expects research data generated as a result of BBSRC support to
be made available with as few restrictions as possible in a timely and
responsible manner to the scientific community for subsequent research
Wellcome Trust (UK), Policy on Data Management and Sharing (2010) Researchers should maximise the availability of data as the maximization
of the value of research depends on fostering a culture in which both
data-generators and data-users act with integrity and transparency in
managing, using, and sharing data
Caulfield et al. Genome Medicine 2012, 4:17
http://genomemedicine.com/content/4/2/17
Page 8 of 11
Empirical research around these and other questions
will go a long way to answering the third question
above, what is the impact of one policy on the other,
and to forging a path toward joined up and nuanced
strategies that are paralleled across sectors and jurisdic-
tions. At the moment, as alluded to above, researchers
simply do not have the requisite training to navigate the
patchwork or come up with ways to effectively blend
them.
Summary
In some respects, this situation defies a conclusion. We
need to collectively and collaboratively forge a middle
path that uses the best elements of both policy trends:
an integrated and flexible approach to innovation. To
some extent, the conflict that appears to exist is more a
function of the disorganized accumulation of seemingly
contradictory broad political mandates than of a true
policy incompatibility. Ultimately much more empirical
research is needed: (1) to document practices and diffi-
culties encountered by researchers trying to navigate
innovations policies and their potentially conflicting
demands; (2) to determine the extent to which commer-
cialization policies and open science policies actually
conflict (or could be made to conflict less); (3) to deter-
mine the degree to which the contemporary innovation
ethos conflicts with existing norms of scientific inquiry;
and (4) to determine if the policy tensions are, in aggre-
gate, harmful (or could be construed to have a more
positive impact on research).
It would seem that the current dilemma is part of a
larger questioning on how best to integrate the various
policy approaches to innovation into a single coherent
and measurable framework that would encompass both
open scientific collaboration and commercialization into
the more global and flexible approach we envision. In
the current transitional period, it is hoped that funding
agencies will be able to develop clear guideposts to
assist researchers in finding their way across this
research conflict (that is, helping them to determine
how best to answer questions in their grant
applications).
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